Charles River Laboratories International, Inc. Common Stock (CRL)
162.66
+12.87 (8.59%)
NYSE · Last Trade: Jul 22nd, 2:17 PM EDT
Detailed Quote
Previous Close
149.79
Open
157.42
Bid
162.52
Ask
162.80
Day's Range
155.48 - 167.83
52 Week Range
91.86 - 254.15
Volume
1,158,845
Market Cap
8.20B
PE Ratio (TTM)
-271.10
EPS (TTM)
-0.6
Dividend & Yield
N/A (N/A)
1 Month Average Volume
760,696
Chart
About Charles River Laboratories International, Inc. Common Stock (CRL)
Charles River Laboratories International is a global provider of laboratory services that support the pharmaceutical, biotechnology, and medical device industries. The company offers a comprehensive suite of research and development solutions, including essential support for drug discovery, safety assessment, and manufacturing. By providing innovative tools and technologies, as well as expertise in areas such as toxicology and genetic testing, Charles River plays a critical role in advancing biomedical research and helping clients develop and bring new therapies to market efficiently and effectively. Read More
Shares of lab services company Charles River Laboratories (NYSE:CRL)
jumped 7.5% in the morning session after the company announced a plasmid DNA manufacturing agreement with Elly's Team, a parent-led foundation working to find a cure for a rare genetic disorder.
Let's delve into the developments on the US markets in the middle of the day on Tuesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.
Charles River Laboratories International, Inc. (NYSE: CRL) and Elly’s Team, a parent-led foundation striving to find a cure for Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech, and Seizures (NEDAMSS), a rare genetic disorder, have announced a plasmid DNA contract development and manufacturing organization (CDMO) agreement. As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), Elly’s Team accessed established gene therapy CDMO capabilities and advisory services to manufacture critical starting materials for a Phase I clinical trial.
Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Monday to uncover the stocks that are gapping in the S&P500 index.
The bid to set clear working rules for the cryptocurrency industry in the U.S. got a booster pill Thursday as the House of Representatives passed key pieces of legislation.
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2025 financial results on Wednesday, August 6th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 6th, at 9:00 a.m. ET.
A number of stocks fell in the morning session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada.
Curious about the market action on Friday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
ARK Invest CEO Cathie Wood agrees with Fundstrat Global Advisors Head of Research Tom Lee and has likened the Circle (NYSE:CRL) IPO to a pivotal moment in the crypto industry, suggesting that institutional investors can no longer ignore the co
Seasoned investor Cathie Wood on Monday praised an analyst from Ark Invest’s Digital Assets team for their successful take on Circle Internet Group, Inc. (NYSE:CRL) from a month ago.
Paolo Ardoino, CEO of stablecoin issuer Tether (CRYPTO: USDT), said Thursday that the company has no plans to go public, despite Circle Internet Financial’s (NYSE:CRL) success on Wall Street.
In a significant development, the Senate passed the GENIUS Act on Tuesday, a bill establishing the country’s first regulatory framework for dollar-pegged stablecoins.
Wall Street’s bearish price targets for the stocks in this article signal serious concerns.
Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a recycling program, developed in partnership with international recycling leader TerraCycle®, to give new life to single-use plastic cartridges. This groundbreaking collaboration offers users of Charles River’s Endosafe® bacterial endotoxin testing (BET) cartridge technology an avenue to responsibly recycle single-use plastic cartridges used specifically for routine water testing. The cartridge recycling program reaffirms Charles River’s ongoing commitment to minimize the Company’s environmental footprint and offer a service to assist clients in meeting their sustainability goals.
Tobi Lütke, CEO of Shopify Inc. (NASDAQ:SHOP), said Thursday that the firm has partnered with Coinbase Global Inc. (NASDAQ:COIN) to integrate USD Coin (CRYPTO:
Lab services company Charles River Laboratories (NYSE:CRL) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 2.7% year on year to $984.2 million. Its non-GAAP profit of $2.34 per share was 12.8% above analysts’ consensus estimates.
Tarun Anand, KPMG’s Blockchain and Digital Asset Consultant, said stablecoins, real-world asset tokenization and decentralized physical infrastructure networks will be the key cryptocurrency narratives to watch out for in the next few years.
Venture capitalist Chamath Palihapitiya admired Circle Internet Group’s (NYSE:CRL) successful Wall Street debut on Monday, suggesting it could pave the way for more cryptocurrency companies to enter public markets.
